⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926696 | 0.70 | — | — | |
| SCHEMBL3431407 | 0.70 | — | — | |
| SCHEMBL722863 | 0.70 | — | — | |
| SCHEMBL2981077 | 0.70 | — | — | |
| SCHEMBL5929425 | 0.70 | — | — | |
| SCHEMBL374101 | 0.70 | — | — | |
| SCHEMBL10597703 | 0.67 | — | — | |
| SCHEMBL307358 | 0.67 | — | — | |
| SCHEMBL3984628 | 0.67 | — | — | |
| SCHEMBL608831 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-20 | — | — | US | claimed |
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-06 | — | — | US | claimed |
| EP-4321504-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | claimed |
| EP-4321503-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED THEREBY, PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME, PREPARATION THEREOF, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | claimed |
| CN-114341103-B | Aminoguanhydrazones as retrograde transport stabilizers useful in the treatment of neurological diseases | 圣拉斐尔医院有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-115850135-A | Sulfur-containing Janus type ionizable liposome and application thereof | 喻国灿 | 2023-03-28 | — | — | CN | claimed |
| CN-115515925-A | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115515926-A | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115197080-A | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-115197078-A | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition | 厦门赛诺邦格生物科技股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | claimed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | claimed |
| US-5476849-A | Inhibiting advanced glycosylation and/or crosslinking of target protein | THE ROCKEFELLER UNIVERSITY (US) | 1995-12-19 | — | — | US | claimed |
| EP-0635492-A1 | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | claimed |
| EP-0623343-A1 | Ketamine analogues for the treatment of thrombocytopenia | GENENTECH, INC. (US) | 1994-11-09 | — | — | EP | claimed |
| US-5250732-A | Influence replication, differentiation or maturation of platelet progenitor cells | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | claimed |
| EP-0413751-A4 | NEUROLOGICALLY ACTIVE COMPOUNDS | — | 1992-07-22 | — | — | EP | claimed |
| EP-0413751-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | NAFTCHI, N., Eric (US) | 1991-02-27 | — | — | EP | claimed |
| WO-1989010744-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | NAFTCHI N ERIC (US) | 1989-11-16 | — | — | WO | claimed |
| EP-0021184-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON SECRETIN WITH ENHANCED AND PROTRACTED ACTIVITY, PROCESS FOR THEIR PREPARATION AND DIHYDROXYBENZOYL-L-TYROSINE | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-02-08 | — | — | EP | claimed |